A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-Positive Lymphoid Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Navitoclax (Primary) ; Rituximab (Primary)
- Indications Lymphoproliferative disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.
- 07 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Apr 2018.